Bisamide sarcomere activating compounds and uses thereof

US10899746B2 · kind B2 · utility

Assignees

• AMGEN INC. · US
• CYTOKINETICS, INC. · US

Inventors

• Luke W. Ashcraft · San Francisco, US
• Alessandro Boezio · Somerville, US
• John R. BUTLER · Colton, US
• Aroop Chandra · South San Francisco, US
• Chihyuan Chuang · Millbrae, US
• Scott Collibee · South San Francisco, US
• Mikkel V. Debenedetto · Shrewsbury, US
• Vincent DiMassa · South San Francisco, US
• Russell Graceffa · Hampton, US
• Justin Malinowski · Boston, US
• David Moebius · Westwood, US
• Bradley P. Morgan · Moraga, US
• Joshua Payette · Hollis, US
• Antonio Romero · San Mateo, US
• David J. St. Jean, Jr. · Camarillo, US
• Richard Vargas · Bedford, US
• John Yeoman · Medford, US
• Hanmo Zhang · Sharon, US
• Alan C. Cheng · Cambridge, US
• Felix Gonzalez Lopez De Turiso · San Mateo, US
• Michael G. Johnson · San Diego, US

Key dates

• Filing date: Mar 27, 2020
• Grant date: Jan 26, 2021
• Expiry date: Apr 4, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.